EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report

Charles R Conway, Augustus John Rush, Scott T Aaronson, Mark T Bunker, Charles Gordon, Mark S George, Patricio Riva-Posse, Rebecca M Allen, Ziad Nahas, Christopher L Kriedt, John Zajecka, David L Dunner und 20 weitere

International Journal of Neuropsychopharmacology · 06.01.2026 · 29 (1)

DOI: 10.1093/ijnp/pyaf080 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Neuropsychopharmacology, online erschienen am 13.01.2026. Verfasst von Charles R Conway und 31 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Washington University in St Louis, St Louis, MO, United States. Hauptthemen laut MEDLINE: Vagus Nerve Stimulation, Depressive Disorder, Treatment-Resistant, Major Depressive Disorder, Outcome Assessment, Health Care. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LivaNova, PLC, CMS HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Greater levels of treatment resistance in major depressive disorder (MDD) are associated with lower rates of initial benefit and higher rates of relapse (lower durability).

Objective

Characterize depressive symptoms, function, and quality of life (QoL) over 24 months of adjunctive vagus nerve stimulation (VNS) in participants with markedly treatment-resistant depression.

Design

Prospective, open-label, single-arm, long-term extension study (RECOVER) conducted from September 2019 to April 2025.

Setting

Outpatient.

Participants

Adults with moderate–severe MDD with ≥ 4 failed antidepressant trials in the current episode, randomized to blinded, adjunctive VNS for 12 months, who subsequently received open-label, adjunctive VNS for 12 additional months (n = 214).

Interventions

Vagus nerve stimulation and concomitant psychotropic medications and interventional psychiatric modalities (electroconvulsive therapy, transcranial magnetic stimulation, and ketamine/esketamine) were characterized over the 12-month extension. Main Outcomes and Measures The durability of benefit achieved at 12 months was assessed at 18 and 24 months for depressive symptoms (3 scales), daily function, QoL, a tripartite composite of all 3 domains, and the Clinical Global Impression–Improvement (CGI-I) scale (overall improvement). Loss of benefit and relapse were assessed, along with the emergence of meaningful benefit in participants without benefit at 12 months. Substantial benefit (at least 50% symptom reduction from baseline; CGI-I of 1 or 2; tripartite measures with at least 2 of 3 subscales evidencing benefit) and meaningful benefit thresholds for symptoms (at least 30% reduction from baseline), function, QoL, CGI-I, and the tripartite measure were set a priori.

Results

Most participants with substantial benefit maintained their benefit (18-month median = 78.8%; 24-month median = 79.0% across 5 measures), as did participants with at least meaningful benefit at 12 months (18-month median = 83.1%; 24-month median = 81.3% across 7 measures). Furthermore, many participants with no meaningful benefit at 12 months achieved it at 18 (median = 30.6%) and 24 (median = 37.8%) months. The strong maintenance of benefit was not accounted for by changes in psychotropic medications or interventional psychiatric modalities. Conclusions and Relevance Depressive symptom, daily function, and QoL benefits obtained after 12 months of adjunctive VNS were sustained in about 80% of participants continuing VNS. Approximately 30% with no meaningful benefit at 12 months accrued increased benefit over the subsequent year. Highlights

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Vagus Nerve StimulationDepressive Disorder, Treatment-ResistantMajor Depressive DisorderOutcome Assessment, Health CareHumansMaleFemaleMiddle AgedAdultQuality of LifeProspective StudiesCombined Modality TherapyAntidepressive AgentsAgedSingle-Blind Method

Stichwörter der Autor:innen

difficult-to-treat depressiondurabilitylong-term extensiontreatment-resistant depressionvagus nerve stimulation

Substanzen

Antidepressive Agents

Autor:innen und Institutionen

  • Department of Psychiatry, Washington University in St Louis, St Louis, MO, United States.
  • Duke-NUS Medical School, Singapore.
  • Curbstone Consultant LLC, Dallas, TX, United States.
  • Institute for Advanced Diagnostics and Therapeutics, Sheppard Pratt Health System, Baltimore, MD, United States.
  • LivaNova PLC (or a subsidiary), London, United Kingdom.
  • Department of Psychiatry, Medical University of South Carolina, Charleston, SC, United States.

ORCID-Profile: Brian J Mickey

Förderung

  • LivaNova
  • PLC
  • CMS HHS
  • Centers for Medicare & Medicaid Services

Zitieren

APA

Conway, C. R., Rush, A. J., Aaronson, S. T., Bunker, M. T., Gordon, C., George, M. S., Riva-Posse, P., Allen, R. M., Nahas, Z., Kriedt, C. L., Zajecka, J., Dunner, D. L., Quevedo, J., Sheline, Y., Duffy, W., Mickey, B. J., Stedman, M., Alva, G., Manu, L., …, & Sackeim, H. A. (2026). Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report. International Journal of Neuropsychopharmacology, 29(1). https://doi.org/10.1093/ijnp/pyaf080

Vancouver

Conway CR, Rush AJ, Aaronson ST, Bunker MT, Gordon C, George MS, et al. Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report. International Journal of Neuropsychopharmacology. 2026;29(1). doi:10.1093/ijnp/pyaf080

BibTeX
@article{Conway2026,
  author = {Conway, Charles R and Rush, Augustus John and Aaronson, Scott T and Bunker, Mark T and Gordon, Charles and George, Mark S and Riva-Posse, Patricio and Allen, Rebecca M and Nahas, Ziad and Kriedt, Christopher L and Zajecka, John and Dunner, David L and Quevedo, João and Sheline, Yvette and Duffy, Walter and Mickey, Brian J and Stedman, Mary and Alva, Gustavo and Manu, Lucian and Tran, Quyen and Zorumski, Charles F and Macaluso, Matthew and Banov, Michael and Cusin, Cristina and Bennett, Jeffrey I and Brown, Hunter and Way, Jeffrey and Shy, Olivia and Lee, Ying-Chieh Lisa and McAllister-Williams, Richard Hamish and McIntyre, Roger S and Sackeim, Harold A},
  title = {Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report},
  journal = {International Journal of Neuropsychopharmacology},
  year = {2026},
  volume = {29},
  number = {1},
  doi = {10.1093/ijnp/pyaf080}
}
Kostenlos starten →